Treatment for obesity plateau population
Search documents
Veru outlines 72-week Phase IIb PLATEAU study targeting obesity plateau population following FDA guidance (NASDAQ:VERU)
Seeking Alpha· 2025-12-17 17:01
Group 1 - The article does not provide any relevant content regarding company or industry insights [1]
